Vancomycin control measures at a tertiary-care hospital: Impact of interventions on volume and patterns of use

Infection Control and Hospital Epidemiology

Volumn 19, Issue 4, 1998, Pages 248-253

  Singer, Mary V ^a   Haft, Rachel ^a   Barlam, Tamar ^a   Aronson, Mark ^a   Shafer, Amy ^a   Sands, Kenneth E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

ALGORITHM; ARTICLE; DRUG USE; EDUCATION; GENERAL HOSPITAL; HOSPITAL BED CAPACITY; HUMAN; MEDICAL STAFF; PRACTICE GUIDELINE; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ALGORITHMS; ANTI-BACTERIAL AGENTS; BOSTON; DRUG UTILIZATION REVIEW; GUIDELINE ADHERENCE; HOSPITAL BED CAPACITY, 300 TO 499; HOSPITALS, GENERAL; HUMANS; LOGISTIC MODELS; MEDICAL STAFF, HOSPITAL; PRACTICE GUIDELINES; VANCOMYCIN;

EID: 0032042919     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.2307/30142415     Document Type: Article

References (25)

1. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA 1993;269:598-602.
2. Morris JG Jr, Shay DK, Hebden JN, McCarter RJ Jr, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-259.
3. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR 1993;42:597-599.
4. Lam S, Singer C, Tucci V, Morthland VH, Pfaller MA, Isenberg HD. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. Am J Infect Control 1995;23:170-180.
5. Wells CL, Juni BA, Cameron SB, Mason KR, Dunn DL, Ferrieri P, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995;21:45-50.
6. Wade JJ. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents - a preliminary report. J Hosp Infect 1995;30(suppl):483-493.
7. Boyce JM, Mermel LA, Zervos MJ, Rice LB, Potter-Bynoe G, Giorgio C, et al. Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1995;16:634-637.
8. Noskin GA, Cooper I, Peterson LR. Vancomycin-resistant Enterococcus faecium sepsis following persistent colonization. Arch Intern Med 1995;155:1445-1447.
9. Karanfil LV, Murphy M, Josephson A, Gaynes R, Mandel L, Hill BC, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195-200.
10. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-113.
11. Handwerger S, Raucher B, Altarac D, Monka H, Marchione S, Singh KV, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-755.
12. Noble WC, Viran Z, Gee RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;93: 195-198.
13. Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 1996;124:329-334.
14. Van der Auwera P, Pensart N, Korten V, Murray BE, Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996;173:1129-1136.
15. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
16. Frieden TR, Munsiff SS, Low DE, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342:76-79.
17. Watanakunakorn C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767-769.
18. Evans M, Kortas KJ. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee Guidelines. Infect Control Hosp Epidemiol 1996;17:356-359.
19. Montecalvo MA, Horowitz H, Nadelman R, Nowakowski J, Andryshak C, Colbi D, et al. Controlling IV vancomycin on an oncology unit by infectious disease consultation. In: The 35th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1995; San Francisco, CA. Abstract N15.
20. Anglim AM, Klym B, Byers KE, Scheld WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin resistant Enterococcus faecium. Arch Intern Med 1997;157:1132-1136.
21. Tornieporth NG, Roberts RB, John J, Hafner A, Riley L. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Inf Dis 1996;23:767-772.
22. Soumerai SB, Avorn J. Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA 1990;263:549-556.
23. Soumerai SB, Avorn J. Predictors of physician prescribing change in an educational experiment to improve medication use. Med Care 1987;25:210-221.
24. Soumerai SB, Avorn J. Economic and policy analysis of university-based drug "detailing." Med Care 1986;24:313-331.
25. Schaffner W, Ray WA, Federspiel CF, Miller WO. Improving antibiotic prescribing in office practice: a controlled trial of three educational methods. JAMA 1983;250:1728-1732.